Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Operating Expenses (2016 - 2025)

Sonoma Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $2.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.17% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.5 million, changed 0.39%, while the annual FY2025 figure was $9.2 million, 2.87% down from the prior year.
  • Operating Expenses for Q4 2025 was $2.3 million at Sonoma Pharmaceuticals, down from $2.5 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $3.2 million in Q1 2022 and troughed at $2.0 million in Q1 2023.
  • A 5-year average of $2.4 million and a median of $2.3 million in 2021 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: tumbled 46.28% in 2021 and later rose 24.32% in 2024.
  • Year by year, Operating Expenses stood at $2.2 million in 2021, then increased by 23.32% to $2.7 million in 2022, then decreased by 13.55% to $2.3 million in 2023, then dropped by 0.13% to $2.3 million in 2024, then grew by 1.17% to $2.3 million in 2025.
  • Business Quant data shows Operating Expenses for SNOA at $2.3 million in Q4 2025, $2.5 million in Q3 2025, and $2.6 million in Q2 2025.